Xeris Biopharma Holdings, Inc. (XERS)
Makes medicines treating low blood sugar, periodic paralysis, and Cushing's syndrome.
$8.24+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+53.2%
The outlook
XERS is trading at $8.24 with analyst sentiment strongly positive—the consensus leans Buy with an average target about 37% above current levels. The stock sits above both its 50- and 200-day moving averages and sits roughly two-thirds of the way through its 52-week range, suggesting a steady uptrend in its recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 7 analysts
Price trendAbove its 50- & 200-day averages
52-week range65% of the way from its 52-week low to high
Price targetAvg target +37% vs current price
Analyst price target
~12-month · 7 analysts$11.29average target+37.0% vs now
Now $8.24
Low $8.00High $18.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.42B
52-wk high
$10.08
52-wk low
$4.87
50-day avg
$7.28
200-day avg
$7.08
Trailing P/E
117.7